XML 169 R86.htm IDEA: XBRL DOCUMENT v3.20.4
Segmentation of key figures (Details 10) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations $ 48,659 $ 47,445 $ 44,751
Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 3.00% 6.00%  
Sandoz [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (1.00%) (1.00%)  
Sandoz [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (1.00%) (1.00%)  
Sandoz [member] | Retail Generics [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations $ 7,244 $ 7,590 7,880
Net sales, change in % (5.00%) (4.00%)  
Sandoz [member] | Biopharmaceuticals [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations $ 1,928 $ 1,607 1,436
Net sales, change in % 20.00% 12.00%  
Sandoz [member] | Anti Infectives [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations $ 474 $ 534 543
Net sales, change in % (11.00%) (2.00%)  
Sandoz [member] | Anti Infectives [member] | Anti Infectives sold under Sandoz name [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations $ 694 $ 784 826
Operating segments [member] | Sandoz [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations $ 9,646 $ 9,731 $ 9,859